WO2005011697A3 - Sulfonamide derivatives with activity on protein kinase a and b - Google Patents

Sulfonamide derivatives with activity on protein kinase a and b Download PDF

Info

Publication number
WO2005011697A3
WO2005011697A3 PCT/GB2004/003196 GB2004003196W WO2005011697A3 WO 2005011697 A3 WO2005011697 A3 WO 2005011697A3 GB 2004003196 W GB2004003196 W GB 2004003196W WO 2005011697 A3 WO2005011697 A3 WO 2005011697A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
carbon atoms
optionally substituted
length
protein kinase
Prior art date
Application number
PCT/GB2004/003196
Other languages
French (fr)
Other versions
WO2005011697A2 (en
Inventor
Edward Mcdonald
Fonseca Tatiana Faria De
Vassilios Bavetsias
John Caldwell
Paul Graham Wyatt
Valerio Berdini
Original Assignee
Astex Technology Ltd
Cancer Rec Tech Ltd
Cancer Res Inst Royal
Edward Mcdonald
Fonseca Tatiana Faria De
Vassilios Bavetsias
John Caldwell
Paul Graham Wyatt
Valerio Berdini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Technology Ltd, Cancer Rec Tech Ltd, Cancer Res Inst Royal, Edward Mcdonald, Fonseca Tatiana Faria De, Vassilios Bavetsias, John Caldwell, Paul Graham Wyatt, Valerio Berdini filed Critical Astex Technology Ltd
Publication of WO2005011697A2 publication Critical patent/WO2005011697A2/en
Publication of WO2005011697A3 publication Critical patent/WO2005011697A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compounds for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A or protein kinase B, the compounds having the formula (I°), or being salts or solvates thereof. In formula (I°), n is 0 or 1; A and E are alkylene 2-3 carbon atoms in length optionally substituted by R11 and -X-CH(R6)(R7); G is hydrogen when n is 0 and, when n is 1, G is hydrogen or -X-CH(R6)(R7); R1 is an aryl or heteroaryl group having 5-12 ring members; R2 and R4 are selected from hydrogen, R7, R11 and CH(R6)(R7); R3, R3a and R5 are selected from hydrogen, R11 and -X-CH(R6)(R7); or any one pair or any two non-overlapping pairs selected from R2 and R3; R3 and R4; R2 and R5; R3 and R5; R4 and R5; R3 and R8; and R4 and R8 are linked together in a ring and together form an alkylene chain of 1-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or the pair R2 and R4 are linked together in a ring and together form an alkylene chain of 2-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); and optionally R3 and R3a may be linked together in a ring and together form an alkylene chain of 1-6 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or R6 and R7 together with the carbon atom to which they are attached form a cyclic group having 5-12 ring members; X, R6, R7, R8, R9, R10 and R11 are each as defined in claim 1; and wherein the definitions of, A, E, G, X, n and R1 to R11 are subject to the provisos set ou in claim 1.
PCT/GB2004/003196 2003-07-24 2004-07-23 Sulfonamide derivatives with activity on protein kinase a and b WO2005011697A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0317315A GB0317315D0 (en) 2003-07-24 2003-07-24 Pharmaceutical compounds
GB0317315.0 2003-07-24

Publications (2)

Publication Number Publication Date
WO2005011697A2 WO2005011697A2 (en) 2005-02-10
WO2005011697A3 true WO2005011697A3 (en) 2005-04-21

Family

ID=27772571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003196 WO2005011697A2 (en) 2003-07-24 2004-07-23 Sulfonamide derivatives with activity on protein kinase a and b

Country Status (2)

Country Link
GB (1) GB0317315D0 (en)
WO (1) WO2005011697A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689719A1 (en) * 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
RU2376300C1 (en) * 2005-08-30 2009-12-20 Асахи Касеи Фарма Корпорэйшн Sulfonamide compound
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AR061240A1 (en) 2006-06-20 2008-08-13 Lilly Co Eli COMPOUNDS OF 4-ISOQUINOLIN-PHENOL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS ANTINEOPLASIC AND / OR ANTIVIRAL AGENTS.
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
CN101622243B (en) 2007-02-28 2013-12-04 旭化成制药株式会社 Sulfonamide derivative
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009004792A1 (en) 2007-07-02 2009-01-08 Asahi Kasei Pharma Corporation Sulfonamide compound, and crystal thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2012036512A2 (en) * 2010-09-16 2012-03-22 연세대학교 산학협력단 Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2248235A (en) * 1988-12-26 1992-04-01 Hiroyoshi Hidaka Quinoline-sulphonamides having smooth muscle relaxation activity
WO2001091754A1 (en) * 2000-05-30 2001-12-06 Peptor Ltd. Protein kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2248235A (en) * 1988-12-26 1992-04-01 Hiroyoshi Hidaka Quinoline-sulphonamides having smooth muscle relaxation activity
WO2001091754A1 (en) * 2000-05-30 2001-12-06 Peptor Ltd. Protein kinase inhibitors

Also Published As

Publication number Publication date
WO2005011697A2 (en) 2005-02-10
GB0317315D0 (en) 2003-08-27

Similar Documents

Publication Publication Date Title
CY1118526T1 (en) DYDROPYROZOLOPYRIMININONE PRODUCTS
EA200600225A1 (en) DERIVATIVES OF PIPERAZINE FOR THE TREATMENT OF HIV INFECTIONS
EP1775289A4 (en) Novel imidazolidine derivatives
CY1117132T1 (en) THEAZOLI PRODUCTION
CY1109890T1 (en) 8-Substituted-6,7,8,9-tetrahydropyrimide [1,2-a] pyrimidin-4-one derivative
CY1105554T1 (en) 3- SUBSTITUTE-4-PYRIMIDONE DERIVATIVES
NO20071642L (en) N-Benzenesulfonyl-substituted anilino-pyrimidine analogs
MX2007000505A (en) Substituted oxindol derivatives and medicaments containing the same.
DE602004014347D1 (en) CHINAZOLIN DERIVATIVES AS TGF BETA INHIBITORS
WO2005011697A3 (en) Sulfonamide derivatives with activity on protein kinase a and b
HUP0401478A2 (en) Pyrazolycarboxanilides as fungicides
CY1112214T1 (en) UNITS FOR USE INJURED WITH INFLAMMATES AND IMMUNE
DK1260512T3 (en) Hitherto unknown cyclic amide derivatives
HUP0400837A2 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
BG106390A (en) Novel spiro compounds
TW200630374A (en) Thiazolyldihydroindazoles
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
WO2005111002A3 (en) Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
DE602006020152D1 (en) ARYL ALKYL AND HETEROARYL ALKYL DERIVATIVES OF CYCLOSPORIN A IN THE TREATMENT AND PREVENTION OF VIRUS INFECTION
HUP0401900A2 (en) 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates
EA200801134A1 (en) REPLACED BICYCLIC PYRIMIDON DERIVATIVES
MX339668B (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor.
NO20065327L (en) Process for the preparation of derivatives of 5- [4- (2-hydroxy-propyl) -3,5-dihydro-3H'1, 2,4 (triazin-2-yl) -benzamide.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase